Long-term physical and mental Health-Related Quality of Life in Italian patients post COVID-19 hospitalisation.

Publication date: Jan 08, 2025

Prior evidence suggests that patients’ Health Related Quality of Life (HRQoL) worsens after COVID-19. This study aimed to investigate HRQoL in Italian patients post-hospitalization for COVID-19, focusing on changes in physical and mental HRQoL over time since COVID-19 diagnosis. A cohort of patients hospitalized for COVID-19 at Molinette Hospital in Turin, Italy, was contacted post-discharge to assess HRQoL using the SF-36 questionnaire. Patients completed the questionnaire only once at a different time since diagnosis. This design allowed for the analysis of responses up to three years after diagnosis. Measured scores were compared with normative data from the Italian population using z-scores. HRQoL differences by gender, comorbidities, and self-perception of health status before and after COVID-19 were tested. The effect of time since diagnosis on physical (PCS) and mental (MCS) SF-36 scores was analysed using multiple linear models and stratified analyses. A total of 601 patients completed the questionnaire. HRQoL was significantly lower compared to the normative Italian population. Men and individuals without comorbidities had better HRQoL, and self-perceptions of health status before and after COVID-19 influenced HRQoL. Time since diagnosis was associated with improved PCS, but MCS remained unaffected. Mental health declined in patients using anxiolytics post-COVID-19, and increasing age negatively affected physical health. Our findings highlight the impact of time since diagnosis on HRQoL post-COVID-19 in an Italian population and suggest the need for further investigation into the pandemic’s effects on HRQoL. Physicians should implement measures to improve mental HRQoL post-COVID-19.

Open Access PDF

Concepts Keywords
Hospitalization Long-term
Italian Post COVID-19 hospitalisation
Mcs Quality of life
Pandemic SF-36
Time since diagnosis

Semantics

Type Source Name
disease IDO quality
disease MESH COVID-19
disease MESH health status
drug DRUGBANK Tropicamide
disease MESH Long Covid
drug DRUGBANK Coenzyme M
disease MESH psychological distress
disease MESH anxiety
disease MESH lifestyle
disease MESH infection
drug DRUGBANK Indoleacetic acid
disease MESH multiple sclerosis
disease MESH marital status
disease MESH comorbidity
drug DRUGBANK Cysteamine
drug DRUGBANK Oxygen
disease IDO blood
disease MESH confusion
disease MESH chronic conditions
disease MESH heart disease
disease MESH cancer
disease MESH functional status
disease MESH educational level
drug DRUGBANK Aspartame
drug DRUGBANK Fenamole
pathway REACTOME Release
disease IDO role
disease IDO acute infection
disease MESH sequelae
disease MESH anxiety disorder
disease MESH depressive symptoms
disease MESH syndrome
disease MESH Middle East respiratory syndrome
disease MESH Post traumatic Stress Disorder
pathway REACTOME Reproduction
drug DRUGBANK Trestolone
drug DRUGBANK (S)-Des-Me-Ampa
pathway REACTOME Translation
disease MESH critical illness
disease MESH acute respiratory distress syndrome
disease MESH tic
disease MESH pneumonia
disease MESH Emergency
drug DRUGBANK Chlorhexadol
disease MESH sepsis
disease MESH respiratory failure
disease MESH Metabolic Syndrome

Original Article

(Visited 1 times, 1 visits today)